« Zurück
Home /
A 83-01 (sodium)

A 83-01 (sodium)

ArtNr	HY-10432A-10mg
Hersteller	MedChem Express
CAS-Nr.	2828431-89-4
Menge	10 mg
Quantity options	100 mg 10 mMx1 mL 10 mg 1 mg 50 mg 5 mg
Kategorie	Neuroscience Molecular Targets for Neuroscience Inhibitors & Compound Libraries Small Molecules
Typ	Inhibitors
Specific against	other
Purity	98.43
Formula	C25H19N5NaS
Citations	J Biol Chem. 2022 Aug 12;102374. Science. 2020 Dec 4;370(6521):eaay2002. Acta Pharmacol Sin. 2024 Jul 25. Acta Pharmacol Sin. 2025 Jan 21. Adv Sci (Weinh). 2022 Sep;9(26):e2202505. Adv Sci (Weinh). 2024 Dec 4:e2408852. Adv Sci (Weinh). 2024 Nov 25:e2401227. Adv Sci (Weinh). 2024 Sep 24:e2402299. Am J Physiol Cell Physiol. 2023 May 1. bioRxiv. 2024 August 11. bioRxiv. 2024 Feb 27. bioRxiv. 2024 July 22. bioRxiv. 2024 November 18. bioRxiv. 2025 January 28. Br J Cancer. 2024 Nov 26. Cancer Res. 2025 Feb 24. Cell Death Dis. 2024 Aug 3;15(8):559. Cell Prolif. 2022 Aug 3;e13320. Cell Prolif. 2024 Jan 12:e13599. Cell Rep Med. 2025 Feb 18;6(2):101966. Cell Rep. 2022 Jul 12;40(2):111053. Cell Rep. 2023 May 23;42(6):112546. Cell Stem Cell. 2022 Sep 1;29(9):1346-1365.e10. Cell Stem Cell. 2025 Jan 10:S1934-5909(24)00446-6. Cell Stem Cell. 2025 Jan 7:S1934-5909(24)00450-8. Cell. 2024 Nov 14;187(23):6566-6583.e22. Cells. 2024 Aug 31. FASEB J. 2020 Aug;34(8):11185-11199. FASEB J. 2023 Dec;37(12):e23279. FASEB J. 2023 Jul;37(7):e22983. Front Med. 2021 Sep 23;8:746298. Genome Med. 2024 Apr 24;16(1):60 Gynecol Oncol. 2019 Jun;153(3):639-650. Hum Cell. 2024 Nov 4;38(1):13. Int J Cancer. 2024 Jan 28. Int J Mol Sci. 2023 Dec 29, 25(1), 477. Int J Radiat Oncol Biol Phys. 2023 Oct 9:S0360-3016(23)07970-1. iScience. 2025 Jan 17;28(2):111827. J Pharm Anal. 2023 Sep 22. J Transl Med. 2021 Dec 7;19(1):497. J Vis Exp. 2025 Jan 31:(215). Methods Mol Biol. 2021 Jun 15. Methods Mol Biol. 2022 Dec 15. Methods Mol Biol. 2023 Jun 24. Mol Cancer. 2024 Jan 10;23(1):12. Mol Oncol. 2023 Oct 23. Nano Res. 03 August 2022. Nat Cell Biol. 2022 Jun;24(6):858-871. Nat Commun. 2022 Sep 6;13(1):5237. Nat Genet. 2024 Feb;56(2):294-305. Nat Methods. 2025 Jan 16. Nat Protoc. 2023 Feb 15. Patent. US20220389379A1. Patent. US20240319170A1 Patent. US20240344020A1 Patent. US20240344020A1. Reprod Toxicol. 2023 Dec 12:123:108522. Research Square Preprint. 2021 Jan. Sci Adv. 2021 Apr 14;7(16):eabb2213. Sci Adv. 2023 Dec 22;9(51):eadi5683. Sci Rep. 2025 Mar 12;15(1):8531. SSRN. 2024 May 23. SSRN. 2024 May 30. Stem Cell Res Ther. 2024 Dec 18;15(1):478. Stem Cell Res Ther. 2025 Mar 11;16(1):132. Theranostics. 2021 Mar 14;11(11):5539-5552. Theranostics. 2024 Jan 1;14(3):1049-1064. [1]Tojo M, et al. The ALK-5 inhibitor A-83-01 inhibits Smad signaling and epithelial-to-mesenchymal transition by transforming growth factor-beta. Cancer Sci. 2005 Nov;96(11):791-800. [2]Yamamura S, et al. The activated transforming growth factor-beta signaling pathway in peritoneal metastases is a potential therapeutic target in ovarian cancer. Int J Cancer. 2012 Jan 1;130(1):20-8. [3]Taniguchi Y, et al. Enhanced antitumor efficacy of folate-linked liposomal doxorubicin with TGF-β type I receptor inhibitor. Cancer Sci. 2010 Oct;101(10):2207-13.
Smiles	S=C(N1N=C(C2=NC(C)=CC=C2)C(C3=CC=NC4=CC=CC=C34)=C1)NC5=CC=CC=C5.[Na]
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Versandbedingung	Raumtemperatur
Lieferbar
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	Organoid; TGF-β Receptor
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, sealed storage, away from moisture and light)
Molecular Weight	444.51
Product Description	A 83-01 sodium is a potent inhibitor of TGF-β type I receptor ALK5 kinase, ALK4 and ALK7, with IC50s of 12 nM, 45 nM and 7.5 nM against the transcription induced by ALK5, ALK4 and ALK7, respectively[1].
Manufacturer - Research Area	Cancer
Solubility	DMSO : 100 mg/mL (ultrasonic)
Manufacturer - Pathway	Stem Cell/Wnt; TGF-beta/Smad
Isoform	ALK4; ALK5; ALK7
Clinical information	No Development Reported

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkdatenblatt anfordern

HY-10432A-10mg-safety-datasheet.pdf